Synlogic (NASDAQ:SYBX) Stock Crosses Below 50 Day Moving Average of $1.53

Synlogic, Inc. (NASDAQ:SYBX)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.53 and traded as low as $1.47. Synlogic shares last traded at $1.47, with a volume of 360 shares traded.

Synlogic Price Performance

The business has a fifty day moving average of $1.53 and a 200 day moving average of $1.67. The stock has a market cap of $16.98 million, a price-to-earnings ratio of -0.14 and a beta of 0.92.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of ($0.51) by $0.67. Synlogic had a negative return on equity of 194.73% and a negative net margin of 2,284.65%. On average, analysts expect that Synlogic, Inc. will post -1.98 EPS for the current year.

Institutional Trading of Synlogic

An institutional investor recently raised its position in Synlogic stock. Armistice Capital LLC increased its holdings in shares of Synlogic, Inc. (NASDAQ:SYBX) by 75.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,055,000 shares of the biotechnology company’s stock after purchasing an additional 455,126 shares during the period. Armistice Capital LLC owned approximately 11.48% of Synlogic worth $4,062,000 at the end of the most recent quarter. 63.40% of the stock is currently owned by institutional investors.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.